Anagnostics said this week that Ramcon will sell its HybCell tests to customers in Denmark, Finland, Iceland, Norway, and Sweden.
Specifically, Ramcon will offer Anagnostics' drugs of abuse tests. The immunochemical assays rely on urine or saliva samples to semi-quantitatively test for drugs of abuse and psychotropic substances using the firm's cylindrical HybCell array platform. Ramcon will also sell Anagnostics' recently launched compact-sequencing-based pharmacogenetics tests (BAN 10/26/2010).
Anagnostics has expanded its reach via similar partnerships. The St. Valentin, Austria-based firm has inked deals with Cell.Eng to represent it in Italy, Invicon to sell its products in Germany, and Biogenetix to represent it in the Romanian market.
Birkerød-based Ramcon employs 24 sales support and service personnel. The company represents other players in the array market, including French scanner firm Innopsys, Italian biochip maker Silicon Biosystems, and Affymetrix's Panomics business.
Further details of the deal were not discussed.